18F-FDG PET of patients with Hürthle cell carcinoma

Val Lowe, Brian P. Mullan, Ian D Hay, Brian McIver, Jan Kasperbauer

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Hürthle cell carcinoma is an uncommon differentiated thyroid cancer characterized by an aggressive clinical course and low avidity for 131I. Treatment usually involves an aggressive surgical approach often combined with 131I. 18F-FDG PET has been helpful in the staging and evaluation of many types of aggressive malignancy. No reports to date have described the utility of PET in a series of patients with Hürthle cell cancer. We reviewed our experience with 18F-FDG PET in the care of patients with Hürthle cell carcinoma to determine the likelihood of uptake in these cancers and the effect of 18F-FDG PET on patient care. Methods: Patients with Hürthle cell cancer who were seen between June 2000 and April 2002 and were imaged with 18F-FDG PET were included. Imaging and clinical data were reviewed. PET results were compared with the results of anatomic imaging (CT, sonography, or MRI) and 131I imaging when performed. Patient charts were reviewed to identify any change in management that resulted from the 18F-FDG PET findings. Results: Fourteen 18F-FDG PET scans of 12 patients were obtained in the time frame indicated. All patients had documented Hürthle cell carcinoma. PET showed intense 18F-FDG uptake in all known Hürthle cell cancer lesions but one. PET showed disease not identified by other imaging methods in 7 of the 14 PET scans. PET identified distant metastatic disease (5) or local disease (2) that was more extensive than otherwise demonstrated. In 7 of the 14 scans, the information provided by PET was used to guide or change therapy. Conclusion: Hürthle cell carcinoma demonstrates intense uptake on 18F-FDG PET images. PET improves disease detection and disease management in patients with Hürthle cell carcinoma relative to anatomic or iodine imaging. 18F-FDG PET should be recommended for the evaluation and clinical management of patients with Hürthle cell carcinoma.

Original languageEnglish (US)
Pages (from-to)1402-1406
Number of pages5
JournalJournal of Nuclear Medicine
Volume44
Issue number9
StatePublished - Sep 2003

Fingerprint

Fluorodeoxyglucose F18
Carcinoma
Neoplasms
Positron-Emission Tomography
Patient Care
Disease Management
Thyroid Neoplasms
Iodine
Ultrasonography
Therapeutics

Keywords

  • Emission CT
  • Hürthle cell cancer
  • PET
  • Thyroid neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

18F-FDG PET of patients with Hürthle cell carcinoma. / Lowe, Val; Mullan, Brian P.; Hay, Ian D; McIver, Brian; Kasperbauer, Jan.

In: Journal of Nuclear Medicine, Vol. 44, No. 9, 09.2003, p. 1402-1406.

Research output: Contribution to journalArticle

Lowe, Val ; Mullan, Brian P. ; Hay, Ian D ; McIver, Brian ; Kasperbauer, Jan. / 18F-FDG PET of patients with Hürthle cell carcinoma. In: Journal of Nuclear Medicine. 2003 ; Vol. 44, No. 9. pp. 1402-1406.
@article{9b1328fe9e7945b5aedaf9004441a095,
title = "18F-FDG PET of patients with H{\"u}rthle cell carcinoma",
abstract = "H{\"u}rthle cell carcinoma is an uncommon differentiated thyroid cancer characterized by an aggressive clinical course and low avidity for 131I. Treatment usually involves an aggressive surgical approach often combined with 131I. 18F-FDG PET has been helpful in the staging and evaluation of many types of aggressive malignancy. No reports to date have described the utility of PET in a series of patients with H{\"u}rthle cell cancer. We reviewed our experience with 18F-FDG PET in the care of patients with H{\"u}rthle cell carcinoma to determine the likelihood of uptake in these cancers and the effect of 18F-FDG PET on patient care. Methods: Patients with H{\"u}rthle cell cancer who were seen between June 2000 and April 2002 and were imaged with 18F-FDG PET were included. Imaging and clinical data were reviewed. PET results were compared with the results of anatomic imaging (CT, sonography, or MRI) and 131I imaging when performed. Patient charts were reviewed to identify any change in management that resulted from the 18F-FDG PET findings. Results: Fourteen 18F-FDG PET scans of 12 patients were obtained in the time frame indicated. All patients had documented H{\"u}rthle cell carcinoma. PET showed intense 18F-FDG uptake in all known H{\"u}rthle cell cancer lesions but one. PET showed disease not identified by other imaging methods in 7 of the 14 PET scans. PET identified distant metastatic disease (5) or local disease (2) that was more extensive than otherwise demonstrated. In 7 of the 14 scans, the information provided by PET was used to guide or change therapy. Conclusion: H{\"u}rthle cell carcinoma demonstrates intense uptake on 18F-FDG PET images. PET improves disease detection and disease management in patients with H{\"u}rthle cell carcinoma relative to anatomic or iodine imaging. 18F-FDG PET should be recommended for the evaluation and clinical management of patients with H{\"u}rthle cell carcinoma.",
keywords = "Emission CT, H{\"u}rthle cell cancer, PET, Thyroid neoplasms",
author = "Val Lowe and Mullan, {Brian P.} and Hay, {Ian D} and Brian McIver and Jan Kasperbauer",
year = "2003",
month = "9",
language = "English (US)",
volume = "44",
pages = "1402--1406",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "9",

}

TY - JOUR

T1 - 18F-FDG PET of patients with Hürthle cell carcinoma

AU - Lowe, Val

AU - Mullan, Brian P.

AU - Hay, Ian D

AU - McIver, Brian

AU - Kasperbauer, Jan

PY - 2003/9

Y1 - 2003/9

N2 - Hürthle cell carcinoma is an uncommon differentiated thyroid cancer characterized by an aggressive clinical course and low avidity for 131I. Treatment usually involves an aggressive surgical approach often combined with 131I. 18F-FDG PET has been helpful in the staging and evaluation of many types of aggressive malignancy. No reports to date have described the utility of PET in a series of patients with Hürthle cell cancer. We reviewed our experience with 18F-FDG PET in the care of patients with Hürthle cell carcinoma to determine the likelihood of uptake in these cancers and the effect of 18F-FDG PET on patient care. Methods: Patients with Hürthle cell cancer who were seen between June 2000 and April 2002 and were imaged with 18F-FDG PET were included. Imaging and clinical data were reviewed. PET results were compared with the results of anatomic imaging (CT, sonography, or MRI) and 131I imaging when performed. Patient charts were reviewed to identify any change in management that resulted from the 18F-FDG PET findings. Results: Fourteen 18F-FDG PET scans of 12 patients were obtained in the time frame indicated. All patients had documented Hürthle cell carcinoma. PET showed intense 18F-FDG uptake in all known Hürthle cell cancer lesions but one. PET showed disease not identified by other imaging methods in 7 of the 14 PET scans. PET identified distant metastatic disease (5) or local disease (2) that was more extensive than otherwise demonstrated. In 7 of the 14 scans, the information provided by PET was used to guide or change therapy. Conclusion: Hürthle cell carcinoma demonstrates intense uptake on 18F-FDG PET images. PET improves disease detection and disease management in patients with Hürthle cell carcinoma relative to anatomic or iodine imaging. 18F-FDG PET should be recommended for the evaluation and clinical management of patients with Hürthle cell carcinoma.

AB - Hürthle cell carcinoma is an uncommon differentiated thyroid cancer characterized by an aggressive clinical course and low avidity for 131I. Treatment usually involves an aggressive surgical approach often combined with 131I. 18F-FDG PET has been helpful in the staging and evaluation of many types of aggressive malignancy. No reports to date have described the utility of PET in a series of patients with Hürthle cell cancer. We reviewed our experience with 18F-FDG PET in the care of patients with Hürthle cell carcinoma to determine the likelihood of uptake in these cancers and the effect of 18F-FDG PET on patient care. Methods: Patients with Hürthle cell cancer who were seen between June 2000 and April 2002 and were imaged with 18F-FDG PET were included. Imaging and clinical data were reviewed. PET results were compared with the results of anatomic imaging (CT, sonography, or MRI) and 131I imaging when performed. Patient charts were reviewed to identify any change in management that resulted from the 18F-FDG PET findings. Results: Fourteen 18F-FDG PET scans of 12 patients were obtained in the time frame indicated. All patients had documented Hürthle cell carcinoma. PET showed intense 18F-FDG uptake in all known Hürthle cell cancer lesions but one. PET showed disease not identified by other imaging methods in 7 of the 14 PET scans. PET identified distant metastatic disease (5) or local disease (2) that was more extensive than otherwise demonstrated. In 7 of the 14 scans, the information provided by PET was used to guide or change therapy. Conclusion: Hürthle cell carcinoma demonstrates intense uptake on 18F-FDG PET images. PET improves disease detection and disease management in patients with Hürthle cell carcinoma relative to anatomic or iodine imaging. 18F-FDG PET should be recommended for the evaluation and clinical management of patients with Hürthle cell carcinoma.

KW - Emission CT

KW - Hürthle cell cancer

KW - PET

KW - Thyroid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0142243411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142243411&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 1402

EP - 1406

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -